Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.71 |
| ▸ | HINT1 | P49773 | 4/20 | 0.63 |
| ▸ | NT5E | P21589 | 2/20 | 0.63 |
| ▸ | PNP | P00491 | 1/20 | 0.60 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.60 |
| ▸ | GSK3A | P49840 | 2/20 | 0.59 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.59 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.59 |
| ▸ | TGM2 | P21980 | 1/20 | 0.58 |
| ▸ | STING1 | Q86WV6 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.57 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.57 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.57 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.57 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Guanosine SCHEMBL2829865 | 0.97 | HPGD (0.76) | HPGDHINT1NT5EPNPPAX8 | |
| Guanosine SCHEMBL11986902 | 0.97 | HPGD (0.76) | HPGDHINT1NT5EPNPPAX8 | |
| Guanosine SCHEMBL531207 | 0.97 | HPGD (0.76) | HPGDHINT1NT5EPNPPAX8 | |
| Guanosine SCHEMBL24049416 | 0.97 | HPGD (0.76) | HPGDHINT1NT5EPNPPAX8 | |
| Guanosine SCHEMBL20750695 | 0.97 | HPGD (0.76) | HPGDHINT1NT5EPNPPAX8 | |
| Guanosine SCHEMBL24049608 | 0.97 | HPGD (0.76) | HPGDHINT1NT5EPNPPAX8 | |
| Guanosine SCHEMBL24049467 | 0.97 | HPGD (0.76) | HPGDHINT1NT5EPNPPAX8 | |
| Guanosine SCHEMBL24049417 | 0.97 | HPGD (0.76) | HPGDHINT1NT5EPNPPAX8 | |
| Guanosine SCHEMBL8593215 | 0.97 | HPGD (0.76) | HPGDHINT1NT5EPNPPAX8 | |
| Guanosine SCHEMBL413586 | 0.97 | HPGD (0.76) | HPGDHINT1NT5EPNPPAX8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6015573-A | TREATMENT OF RESISTANT HERPES VIRUS WITH NUCLEOSIDE PHOSPHATE ESTERS | RESOLUTION PERFORMANCE PRODUCTS LLC | 2000-01-18 | — | — | US | claimed |
| US-20110105417-A1 | Drug Conjugates | THE CURATORS OF THE UNIVERSITY OF MISSOURI | 2011-05-05 | — | — | US | disclosed |
| WO-2009158633-A1 | DRUG CONJUGATES | CURATORS OF THE UNIVERSITY OF MISSOURI ON BEHALF OF THE UNIVERSITY OF MISSOURI-KANSAS CITY (US) | 2009-12-30 | — | — | WO | disclosed |
| US-20080027010-A1 | Treatment of refractory cancers using Na+/K+-ATPase inhibitors | BIONAUT PHARMACEUTICALS, INC. | 2008-01-31 | — | — | US | disclosed |
| US-7262177-B2 | Conjugates of glycosylated/galactosylated peptide, bifunctional linker, and nucleotidic monomers/polymers, and related compositions and methods of use | CELL WORKS THERAPEUTICS, INC. (US) | 2007-08-28 | — | — | US | disclosed |
| US-20070142317-A1 | Topical composition for treatment of skin disorders | QLT USA, INC. (US) | 2007-06-21 | — | — | US | disclosed |
| US-20050250679-A1 | Conjugates of glycosylated/galactosylated peptide, bifunctional linker, and nucleotidic monomers/polymers, and related compositions and methods of use | Cell Works Therapeutics, Inc., Delaware corporations | 2005-11-10 | — | — | US | disclosed |
| WO-2005065668-A2 | TOPICAL COMPOSITIONS COMPRISING HALO-DEOXYADENOSINES FOR TREATMENT OF SKIN DISORDERS | QLT USA, INC. (US) | 2005-07-21 | — | — | WO | disclosed |
| US-6906182-B2 | Conjugates of glycosylated/galactosylated peptide, bifunctional linker, and nucleotidic monomers/polymers, and related compositions and method of use | CELL WORKS THERAPEUTICS, INC. (US) | 2005-06-14 | — | — | US | disclosed |
| WO-2002043771-A9 | CONJUGATES OF GLYCOSYLATED/GALACTOSYLATED PEPTIDE | CELL WORKS INC (US) | 2004-04-29 | — | — | WO | disclosed |
| EP-1355672-A2 | CONJUGATES OF GLYCOSYLATED/GALACTOSYLATED PEPTIDE, BIFUNCTIONAL LINKER, AND NUCLEOTIDIC MONOMERS/POLYMERS, AND RELATED COMPOSITIONS AND METHODS OF USE | Cell Works Inc. (US) | 2003-10-29 | — | — | EP | disclosed |
| US-20030032584-A1 | Conjugates of glycosylated/galactosylated peptide, bifunctional linker, and nucleotidic monomers/polymers, and related compositions and method of use | CELL WORKS INC. (US) | 2003-02-13 | — | — | US | disclosed |
| WO-2002043771-A2 | CONJUGATES OF GLYCOSYLATED/GALACTOSYLATED PEPTIDE | CELL WORKS INC. (US) | 2002-06-06 | — | — | WO | disclosed |
| EP-0227844-B1 | ANTIVIRAL DRUG | TEIJIN LIMITED (JP) | 1992-05-13 | — | — | EP | disclosed |
| US-4868162-A | 5-HALO-2*-DEOXYURIDINE DERIVATIVE | TEIJIN LIMITED (JP) | 1989-09-19 | — | — | US | disclosed |
| EP-0227844-A1 | ANTIVIRAL DRUG | TEIJIN LIMITED (JP) | 1987-07-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142317-A1 | Topical composition for treatment of skin disorders | CDA, ADA, DCTD | HPGD 1662/4885HINT1 376/4885NT5E 37/4885 |
| US-20030032584-A1 | Conjugates of glycosylated/galactosylated peptide, bifunctional linker, and nucleotidic monomers/polymers, and related compositions and method of use | LNPEP, B3GAT3, GALNT1 | HPGD 4285/4885HINT1 2702/4885NT5E 233/4885 |
| US-20080027010-A1 | Treatment of refractory cancers using Na+/K+-ATPase inhibitors | ATP1A4, ATP1A3, ATP1B3 | HPGD 2021/4885HINT1 324/4885NT5E 551/4885 |
| US-20050250679-A1 | Conjugates of glycosylated/galactosylated peptide, bifunctional linker, and nucleotidic monomers/polymers, and related compositions and methods of use | LNPEP, B3GAT3, GALNT1 | HPGD 4301/4885HINT1 2865/4885NT5E 259/4885 |
| US-20110105417-A1 | Drug Conjugates | ABCB1, SLCO2B1, ABCG2 | HPGD 1997/4885HINT1 3256/4885NT5E 1265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.